Active Ingredient(S)
Fexofenadine hydrochloride USP, 180 mg
The following Structured Product Label (SPL) was submitted to the FDA by Walmart Inc. for the product Equate Allergy Relief (NDC 49035-366). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding active ingredient(s), purpose, use(s), do not use, ask a doctor or pharmacist before use if, when using this product, stop use and ask a doctor if, if pregnant or breast-feeding,, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
Fexofenadine hydrochloride USP, 180 mg
Antihistamine
temporarily relieves these symptoms due to hay fever or other upper respiratory allergies:
if you have ever had an allergic reaction to this product or any of its ingredients.
you have kidney disease. Your doctor should determine if you need a different dose.
an allergic reaction to this product occurs. Seek medical help right away.
ask a health professional before use.
In case of overdose, get medical help or contact a Poison Control Center right away
| adults and children 12 years of age and over | take one 180 mg tablet with water once a day; do not take more than 1 tablet in 24 hours |
| children under 12 years of age | do not use |
| adults 65 years of age and older | ask a doctor |
| consumers with kidney disease | ask a doctor |
Colloidal silicon dioxide, hypromellose, light liquid paraffin, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, pregelatinized starch, red iron oxide, sodium starch glycolate, talc, titanium dioxide and yellow iron oxide.
call toll-free weekdays 9 AM to 5 PM EST at 1-888-588-1418
Fexofenadine Hydrochloride Tablets, USP 180 mg 30 ct Container Label
Fexofenadine Hydrochloride Tablets, USP 180 mg 30ct Carton Label
Fexofenadine Hydrochloride Tablets, USP 180 mg 60 ct Carton Label
* Please review the disclaimer below.